- Bupa Platinum consultant
- Fee assured
- Verified account
- Open Referral network
Specialises in
- Breast
Offers
- Face-to-face consultations
- Video and telephone consultations
- Home chemotherapy
About me
Dr Shiroma De Silva-Minor is a Consultant Clinical Oncologist. She was appointed as an NHS Consultant in 2008 till 2024, at The Oxford University Hospitals NHS Trust. Shiroma specialises inOncology treatments for breast cancers.
Shiroma graduated from University of Wales College of Medicine, Cardiff in 1995 and became a Member of the Royal College of Physicians (UK) in 1999. Having chosen to specialise in Clinical Oncology, she trained as a specialist registrar in London, working at nationally renowned cancer centres including UCL The Middlesex Hospital, The Royal Free and The Royal Marsden Hospital. In 2003, Shiroma became a Fellow of the Royal College of Radiologists (UK) in 2003.
During a fellowship in Head and Neck Radiation Oncology at the prestigious Princess Margaret Hospital, Toronto, Shiroma was awarded the Prize for Academic Excellence by the institution and The University of Toronto for her research into the use of PET CT for identifying head and neck tumours for radiotherapy treatment.
Shiroma has presented her research at international conferences including The Annual meeting of the Canadian Association of Radiation Oncologists (CARO) in British Columbia and the American Society for Therapeutic Radiology and Oncology (ASTRO) in Colorado and in Philadelphia and at the European Society of Therapeutic Radiation and Oncology (ESTRO).
As a Clinical Oncologist, Shiroma oversees the whole non-surgical aspects of a patients journey from genetic testing, counselling; through to treatments including chemotherapy, external beam radiotherapy (including partial breast treatment), Intraoperative radiotherapy, PARP inhibitors, CDK4/6 inhibitors, clinical trials.
Shiroma is interested in research and is currently collaborating on a metanalysis with the Early Breast Cancer Trialists' Collaborative Group (EBCTCG) to bring together the research on radiotherapy clinical trials to better understand how to optimally treat breast cancer patients with radiotherapy.
Shiroma is a member of the Advisory Board on Cancer in Pregnancy (ABCIP), an international panel of experts in managing breast cancer in pregnancy.
Shiroma has been an expert member of the Breast Cancer Committee for the National Institute of Health and Care Excellence (NICE), involved in updating the national guidelines on breast cancer management.
Shiroma is a passionate advocate for empowering her patients to be involved in their management decisions. Treatment is completely bespoke to individual patients, their specific tumour subtype, taking into consideration the individual's beliefs, wishes and personal circumstances.
Areas of interest
Breast oncology specialising in Male Breast cancers, Triple negative breast cancers, Breast cancer in Pregnancy, Her 2 positive cancers,
Radiotherapy;
Chemotherapy;
Clinical Trials;
Intraoperative radiotherapy;
External beam radiotherapy;
PARP inhibitors;
CDK4/6 inhibitors
Liquid biopsis/ genomic profiling of breast cancers
Genetic counselling and testing
Medical secretaries
- Joyce Harris
- Dept of Oncology, Churchill Hospital Old Road Headington OXFORD OX3 7LJ
- 07412 281560
- sdsmprivate@gmail.com
- To pay your remaining balance, please call
- 01702 382362
Information for healthcare professionals (Bupa patients only, last 12 months)
-
X0003
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-21 days - (>50)
GenesisCare, Oxford (>50) Cromwell Hospital (5-50)
-
X0004
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-28 days - (>50)
GenesisCare, Oxford (5-50)
-
X0007
Clinical supervision of external beam radiotherapy, up to and including 15 fractions or part thereof - (5-50)
GenesisCare, Oxford (5-50)
-
X0002
Clinical supervision and planning for the delivery of chemotherapy and/or systemic anti-cancer therapy for 1-14 days - (5-50)
GenesisCare, Oxford (5-50)
-
X3590
Intravenous infusion (as sole procedure) - (5-50)
- Show All (10 )...